New antibody treatment could calm sudden attacks of rare nerve disorder
NCT ID NCT07182409
First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 25 times
Summary
This study tests whether monoclonal antibodies can safely reduce disability during sudden attacks of neuromyelitis optica spectrum disorder (NMOSD), a rare disease that inflames the nerves and eyes. Forty adults in the acute phase of NMOSD will receive the antibody treatment, and researchers will track their recovery over six months. The goal is to find better ways to manage these attacks and understand which patients respond best.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NMOSD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.